The invention provides biomarkers that are modulated in Alzheimer's disease including IL- la, PDGF-BB, TNF-a, M-CSF, G-CSF, GNDF, eotaxin 2, MCP-3, PARC, AgRP, MSP-a, and BTC. Described are methods for preventing, treating, alleviating symptoms of, or delaying the development of Alzheimer's Disease (AD) in an individual diagnosed with Alzheimer's Disease or at risk for developing the disease by modulating the biological activity of, or the levels of any one or more of these AD-associated biomarkers. 'Modulation of biomarker levels by administration of biomarker proteins, biologically active fragments thereof, agonists, antagonists and antibodies are provided.
